Stryker Corporation
SYK
$304.00
+0.86%
Stryker Corporation designs, manufactures, and markets medical equipment, instruments, consumable supplies, and implantable devices spanning reconstructive orthopaedics (hips, knees, extremities), MedSurg (endoscopy, operating room equipment, hospital beds), and neurovascular/robotic surgery platforms, with roughly three-quarters of revenue generated in the United States. It is one of the three largest global competitors in reconstructive implants and holds the leadership position in operating room equipment, giving it a scale-and-breadth moat that supports cross-selling through hospital capital cycles. The current investor debate centers on whether Stryker can sustain high-single-digit organic growth and margin expansion against a backdrop of soft MedSurg capital spending, tariff and input-cost pressure, and a stock that has de-rated sharply over the past year despite solid reported results. Recent strategic activity, including the completed acquisition of Amplitude Vascular Systems to add next-generation intravascular lithotripsy technology to its peripheral vascular portfolio, signals management's intent to keep buying growth in higher-velocity vascular categories while defending its core orthopaedics franchise.…
SYK
Stryker Corporation
$304.00
Related headlines
Investment Opinion: Should I buy SYK Today?
Rating: Buy (moderate conviction). The thesis is that Stryker's 9.4% revenue growth, 68.3% gross margin, and $4.70B TTM free cash flow support a franchise that is temporarily de-rated, with the consensus buy rating (1.69 mean) and $362.62 average target implying 18.1% upside. The stock's 19.8% one-year decline has compressed the forward PE to 18.4x, offering a reasonable entry point for a defensive medtech leader.
Supporting evidence: (1) forward PE of 18.43x versus trailing 41.4x, reflecting expected EPS growth to $23.05; (2) Q2 2026 revenue growth of 9.42% YoY with gross margin expansion to 68.27% from 62.27%; (3) TTM free cash flow of $4.702B and net margin of 12.9%; (4) 18.1% upside to the $362.62 average analyst target, with a low target of $298 only 3.0% below the current price. The dividend yield of 0.96% and payout ratio of 39.6% add modest income support.
Risks and conditions: the biggest risks are margin inconsistency (Q1 2026 operating margin of 15.5%), premium valuation (5.35x sales, 23.2x EV/EBITDA), and MedSurg capital spending weakness. The rating would upgrade to a stronger Buy if operating margins sustainably exceed 20% and forward PE stays below 20x; it would downgrade to Hold if revenue growth decelerates below 7% or if gross margin falls below 63%. Valuation verdict: fairly valued to slightly undervalued relative to the company's growth and cash flow, but not deeply discounted versus peers.
Sign up to view all
SYK 12-Month Price Forecast
Stryker's fundamental trajectory is improving: Q2 2026 revenue grew 9.42% with gross margin up 600 basis points year-over-year, and the forward PE of 18.4x is reasonable for a medtech leader with $4.7B in free cash flow. The stock's 19.8% one-year decline and -32.9% relative strength have created a valuation reset, while analyst consensus remains a buy with an 18.1% upside to the average target. The main risk is margin inconsistency, as Q1 2026 operating margin of 15.5% showed the company is not immune to cost pressure. I would upgrade to high confidence if operating margins sustainably exceed 20% for two consecutive quarters, and downgrade to neutral if revenue growth falls below 7% or gross margin drops below 63%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $362.62 and implied upside of +19.3% versus the current price.
Average Target
$362.62
0 analysts
Implied Upside
+19.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$298 - $465
Analyst target range
Bulls vs Bears: SYK Investment Factors
The bull case rests on accelerating 9.4% revenue growth, expanding gross margins (68.3% in Q2 2026), a consensus buy rating with 18% upside to the $362.62 average target, and a forward PE of 18.4x that looks reasonable for a defensive medtech leader. The bear case is equally grounded: the stock is down 19.8% over one year with -32.9% relative strength versus the S&P, still trades at 41.4x trailing earnings and 5.35x sales, and has exhibited a -30.5% max drawdown with erratic quarterly margins. On balance, the evidence slightly favors the bulls because the forward earnings multiple has compressed to a level that already discounts much of the bad news, and analyst sentiment remains firmly positive. The single most important tension is whether Stryker can convert its 9%+ top-line growth into consistent margin expansion—if operating margins hold above 19-20% and the forward PE stays below 20x, the stock likely re-rates higher; if margins slip back toward the 15.5% seen in Q1 2026, the de-rating could resume.
Bullish
- Revenue growth accelerating to 9.4% YoY: Q2 2026 revenue of $6.589B grew 9.42% year-over-year versus $6.022B in Q2 2025, and accelerated from Q1 2026's $6.020B. Gross margin also expanded to 68.27% in Q2 2026 from 62.27% a year earlier, showing growth is coming with better profitability.
- Analyst consensus buy with 18% upside: 26 analysts rate SYK a buy (mean recommendation 1.69) with an average target of $362.62, implying 18.1% upside from the $307.15 current price. The high target of $465 implies 51.4% upside, and even the low target of $298 is only 3.0% below the current price.
- Forward PE of 18.4x is historically cheap: SYK trades at 18.43x forward EPS of $23.05 versus a trailing PE of 41.4x, reflecting expected earnings normalization. The forward multiple is well below the stock's own recent history and offers a reasonable entry point for a franchise with 9%+ revenue growth and 19.5% operating margins.
- Strong FCF and balance sheet: TTM free cash flow is $4.702B against a $134.3B market cap, and the current ratio of 1.89 and debt-to-equity of 0.73 indicate a solid balance sheet. Q2 2026 net income of $1.276B (19.4% net margin) supports continued investment in M&A like the Amplitude Vascular Systems deal.
Bearish
- Stock down 19.8% over one year: SYK has fallen 19.82% over the past year and 11.78% YTD, massively underperforming the S&P 500's +13.13% 1-year and +11.45% YTD returns. The 1-year relative strength of -32.95% signals a severe de-rating that has not yet reversed.
- Trailing valuation still rich at 41.4x: Despite the selloff, SYK trades at 41.4x trailing earnings, 5.35x sales, 6.0x book, and 23.2x EV/EBITDA. The PEG ratio of 5.16 is elevated, meaning investors are still paying a premium that requires flawless execution to justify.
- Earnings volatility and margin inconsistency: Quarterly EPS has swung from $1.43 in Q4 2024 to $3.32 in Q2 2026, and operating margin ranged from 15.5% in Q1 2026 to 27.3% in Q4 2025. Q1 2026 net margin of 12.4% was well below Q2 2026's 19.4%, showing uneven profitability.
- Recent 30% drawdown shows fragility: The stock's max drawdown of -30.54% and its fall from a 52-week high of $389.33 to a low of $267.00 demonstrate significant downside volatility. The sharp drop from $352.25 on July 29 to $270.01 on September 10 shows how quickly sentiment can deteriorate.
SYK Technical Analysis
Beta
0.78
0.78x market volatility
Max Drawdown
-30.5%
Largest decline past year
52-Week Range
$267-$389
Price range past year
Annual Return
-19.1%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | +10.4% | +0.9% |
| 3m | -12.7% | +4.1% |
| 6m | +3.1% | +7.2% |
| 1y | -19.1% | +12.4% |
| ytd | -12.7% | +13.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Quarterly Revenue
$6.6B
2026-06
Revenue YoY Growth
+9.4%
YoY Comparison
Gross Margin
68.3%
Latest Quarter
Free Cash Flow
$4.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 38x~46x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on earnings quality and margin consistency. Q1 2026 operating margin fell to 15.5% and net margin to 12.4%, versus 25.2% and 19.4% in Q2 2026, showing that quarterly profitability is uneven and sensitive to product mix and one-time items. The trailing PE of 41.4x and PEG of 5.16 mean the valuation depends on continued earnings growth; any slowdown in the $23.05 consensus EPS estimate would compress the multiple sharply. Debt-to-equity of 0.73 and a current ratio of 1.89 are manageable, but the company's acquisitive strategy (e.g., Amplitude Vascular Systems) adds integration and intangible amortization risk that can weigh on reported earnings.
Market and competitive risks include valuation compression and sector rotation. SYK trades at 5.35x sales and 23.2x EV/EBITDA, a premium that leaves little room for disappointment in a sector where peers like Boston Scientific have shown trial-result volatility. The beta of 0.781 provides some downside cushion, but the stock's -32.9% one-year relative strength versus the S&P shows it has been a persistent underperformer, and soft MedSurg capital spending plus tariff and input-cost pressure could keep margins under pressure. The recent Amplitude acquisition signals a need to buy growth in peripheral vascular, which may intensify competition with larger medtech rivals.
Worst-case scenario: a combination of MedSurg capital spending cuts, tariff-driven gross margin compression below 63%, and a miss on the $23.05 EPS consensus could drive the stock back to its 52-week low of $267.00, a decline of 13.1% from the current $307.15. A more severe outcome, such as a broad medtech de-rating that pushes the forward PE below 15x on lowered estimates, could test the $250 area, implying roughly -18.6% downside. The historical max drawdown of -30.54% shows that a decline toward $213 is not unprecedented in a stress scenario, representing about -30.6% from current levels.
FAQ
The most severe risk is margin inconsistency: Q1 2026 operating margin fell to 15.5% versus 25.2% in Q2 2026, and any repeat could trigger a de-rating from the 41.4x trailing PE. Second is valuation compression: at 5.35x sales and 23.2x EV/EBITDA, the stock has little room for disappointment, and the -30.54% max drawdown shows how quickly sentiment can turn. Third is MedSurg capital spending weakness and tariff/input-cost pressure, which could keep gross margin below the 68.27% seen in Q2 2026. Fourth is acquisition integration risk from Amplitude Vascular Systems, which may dilute near-term earnings.
The 12-month forecast has three scenarios: a 30% probability bull case targeting $400-$465 (analyst high $465), a 50% probability base case targeting $340-$380 (analyst average $362.62), and a 20% probability bear case targeting $267-$298 (52-week low $267, analyst low $298). The base case is most likely, assuming revenue growth of 8-9%, operating margin near 19-20%, and EPS meeting the $23.05 consensus. The key assumption is that gross margin holds above 63% and MedSurg capital spending does not deteriorate further.
SYK trades at 41.4x trailing earnings, 5.35x sales, 6.0x book, and 23.2x EV/EBITDA, which is a premium to the broader market but below the stock's own recent history given the 19.8% one-year decline. The forward PE of 18.43x is the key metric, reflecting expected EPS growth to $23.05 and suggesting the market is pricing in earnings normalization rather than multiple expansion. The PEG ratio of 5.16 is elevated, meaning the market still pays up for growth. Relative to its growth and cash flow, the stock looks fairly valued to slightly undervalued, but it is not deeply discounted versus medtech peers.
From a risk/reward perspective, SYK offers an 18.1% upside to the $362.62 average analyst target against a 13.1% downside to the 52-week low of $267.00, a roughly 1.4:1 reward-to-risk ratio. The forward PE of 18.43x is reasonable for a company growing revenue 9.42% with a 68.27% gross margin and $4.702B in TTM free cash flow. The biggest downside risk is margin inconsistency, as Q1 2026 operating margin of 15.5% showed earnings can be volatile. It is a good buy for long-term investors with a 2-3 year horizon who can tolerate near-term volatility, but less suited for short-term traders given the stock's -30.54% max drawdown and -19.8% one-year decline.
SYK is best suited for long-term investment given its defensive healthcare profile (beta 0.781), 0.96% dividend yield, and 9%+ revenue growth, which require time to compound. The stock's -30.54% max drawdown and -19.8% one-year decline show significant short-term volatility, making it a poor candidate for trading. Earnings visibility is moderate, with quarterly EPS ranging from $1.43 to $3.32 over the past two years, so a minimum holding period of 2-3 years is recommended to ride out margin fluctuations and capture the re-rating toward the $362.62 average target.